Industry

DUBLIN–(BUSINESS WIRE)–The “Asia Pacific Antibody Drug Conjugates Market – Forecasts from 2022 to 2027” report has been added to ResearchAndMarkets.com’s offering. The rapidly increasing number of cancer cases in the Asia Pacific region is one of the prominent reasons anticipated to drive the growth of the antibody-drug conjugates market. Furthermore, drug developers are increasingly investing … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Human Identification – A Global and Regional Analysis: Focus on Offering, Technology, Application, End User, and Region – Analysis and Forecast, 2022-2032” report has been added to ResearchAndMarkets.com’s offering. Global Human identification Market Industry Overview The global human identification market is projected to reach $6,435.6 million by 2032 from $1,385.8 million in 2021, … [Read more…]

WATERTOWN, Mass.–(BUSINESS WIRE)–Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD), prostate cancer and other rare hematologic diseases and cancers, today announced that it will release second quarter 2022 financial results Friday, August 5, 2022. Forma management will host an investment community conference call at 8 a.m. Eastern … [Read more…]

HENDERSON, Nev.–(BUSINESS WIRE)–Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2022 financial results and provide a corporate update on Thursday, August 11, 2022 at 8:30 a.m. Eastern/5:30 a.m. Pacific. Conference Call and Webcast: Thursday, August 11, … [Read more…]

– 200mg and 400mg Once-Daily Doses Achieved Strong Exposure Multiples Over EC90 and Were Generally Safe and Well-Tolerated – Plan to Initiate Phase 2 Study in 4Q 2022 WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced positive … [Read more…]

New Online Registration Required for Live Call to Ask Questions Audio-Only Webcast Still Available on Concert’s Website LEXINGTON, Mass.–(BUSINESS WIRE)–$CNCE #AlopeciaAreata—Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the second quarter of 2022, on Thursday, August 4, 2022, before the U.S. financial markets open. The Company will host … [Read more…]

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that Part A of the Phase 3 CheckMate -914 trial, evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as an adjuvant treatment for patients with localized renal cell carcinoma (RCC) who have undergone full or partial removal of the kidney and who are at moderate or high risk … [Read more…]

NEW YORK–(BUSINESS WIRE)–Colgate-Palmolive Company (NYSE:CL): Net sales increased 5.5%; Organic sales* increased 9.0% with growth in every division and all four categories GAAP EPS declined 13% to $0.72; Base Business EPS* declined 10% to $0.72 GAAP Gross profit margin and Base Business Gross profit margin* both decreased 300 basis points to 57.0% Net cash provided … [Read more…]

Second Sight to change its name to Vivani Medical, Inc. LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Mesenchymal Stem Cells Market Intelligence Report – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering. The Global Mesenchymal Stem Cells Market is projected to reach USD 5,847.88 million by 2027 from USD 2,731.51 million in 2021, at a CAGR 13.52% during the forecast period. Market Statistics: The Americas Mesenchymal Stem … [Read more…]